Singh Itu, Ahuja Madhvi, Lavania Mallika, Pathak Vinay K, Turankar Ravindra P, Singh Vikram, Sengupta Utpal, Das Loretta, Kumar Archana, Saini Geeta B
Stanley Browne Research Laboratory, The Leprosy Mission Community Hospital, New Delhi, Delhi, India.
ICMR-National Institute of Virology, Pune, Maharashtra, India.
Indian J Dermatol Venereol Leprol. 2023 Jan-Mar;89(2):226-232. doi: 10.25259/IJDVL_915_2021.
In endemic regions of several countries, the prevalence of leprosy has not come down to the level of elimination. On the contrary, new cases are being detected in large numbers. Clinically, it is frequently noted that despite completion of multibacillary multidrug therapy for 12 months, the lesions remain active, especially in cases with high bacteriological indices.
The present study focused on finding out the viable number of Mycobacterium leprae during the 12-month regimen of multibacillary multidrug therapy, at six and 12 months intervals and, attempting to determine their role in disease transmission.
Seventy eight cases of multibacillary leprosy cases were recruited from leprosy patients registered at The Leprosy Mission hospitals at Shahdara (Delhi), Naini (Uttar Pradesh) and Champa (Chhattisgarh), respectively. Slit skin smears were collected from these patients which were transported to the laboratory for further processing. Ribonucleic acid was extracted by TRIzol method. Total Ribonucleic acid was used for real-time reverse transcription-polymerase chain reaction (two-step reactions). A standard sample with a known copy number was run along with unknown samples for a reverse transcription-polymerase chain reaction. Patients were further assessed for their clinical and molecular parameters during 6th month and 12th month of therapy.
All 78 new cases showed the presence of a viable load of bacilli at the time of recruitment, but we were able to follow up only on 36 of these patients for one year. Among these, using three different genes, 20/36 for esxA, 22/36 for hsp18 and 24/36 for 16S rRNA cases showed viability of M. leprae at the time of completion of 12 months of multidrug therapy treatment. All these positive patients were histopathologically active and had bacillary indexes ranging between 3+ and 4+. Patients with a high copy number of the Mycobacterium leprae gene, even after completion of treatment as per WHO recommended fixed-dose multidrug therapy, indicated the presence of live bacilli.
Follow up for one year was difficult, especially in Delhi because of the migratory nature of the population. Patients who defaulted for scheduled sampling were not included in the study.
The presence of a viable load of bacilli even after completion of therapy may be one of the reasons for relapse and continued transmission of leprosy in the community.
在一些国家的麻风病流行地区,麻风病的患病率尚未降至消除水平。相反,仍有大量新病例被发现。临床上经常注意到,尽管多菌型麻风患者接受了为期12个月的联合化疗,但皮损仍处于活动状态,尤其是细菌指数较高的患者。
本研究着重于在多菌型麻风联合化疗的12个月疗程中,每隔6个月和12个月,测定存活的麻风分枝杆菌数量,并试图确定其在疾病传播中的作用。
分别从位于德里沙德拉、北方邦奈尼和恰蒂斯加尔邦占巴的麻风病传教医院登记的麻风病患者中招募78例多菌型麻风患者。从这些患者身上采集皮肤涂片,然后运送到实验室进行进一步处理。采用TRIzol法提取核糖核酸。将总核糖核酸用于实时逆转录-聚合酶链反应(两步反应)。在进行逆转录-聚合酶链反应时,将一个已知拷贝数的标准样品与未知样品一起检测。在治疗的第6个月和第12个月,对患者的临床和分子参数进行进一步评估。
所有78例新病例在入组时均显示有存活的杆菌,但我们仅对其中36例患者进行了为期一年的随访。在这些患者中,使用三种不同的基因检测,在完成12个月的联合化疗后,36例患者中,esxA基因检测有存活菌的为20/36,hsp18基因检测有存活菌的为22/36,16S rRNA基因检测有存活菌的为24/36。所有这些呈阳性的患者在组织病理学上均为活动期,细菌指数在3+至4+之间。即使按照世界卫生组织推荐的固定剂量联合化疗方案完成治疗后,麻风分枝杆菌基因拷贝数高的患者仍表明存在活菌。
为期一年的随访存在困难,尤其是在德里,因为当地人口具有流动性。未按计划进行采样的患者未纳入本研究。
即使在完成治疗后仍存在存活的杆菌,可能是麻风病在社区复发和持续传播的原因之一。